We are live on
!
Find out more
AVLSA
Atlas Venture Life Science Advisors Portfolio holdings
AUM
$790M
1-Year Est. Return
223.66%
This Fund
S&P 500
This Quarter
Est. Return
+52.07%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$753M
AUM Growth
+$90.3M
(+14%)
Cap. Flow
-$120M
Cap. Flow
% of AUM
-15.88%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
–
Reduced
4
Closed
2
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
THRD
Third Harmonic Bio
THRD
|
+$56.5M |
| 2 |
VIGL
Vigil Neuroscience
VIGL
|
+$46.4M |
| 3 |
Disc Medicine
IRON
|
+$14.4M |
| 4 |
SION
Sionna Therapeutics
SION
|
+$1.71M |
| 5 |
IMA
ImageneBio Inc
IMA
|
+$535K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
AWG
AT
MTWSIF
VH
M
AI
VCM
SWIG
Atlas Venture Life Science Advisors's Q3 2025 Portfolio in Review
As of Q3 2025, Atlas Venture Life Science Advisors held 11 positions worth $753M, up 14% from $662M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Atlas Venture Life Science Advisors withdrew a net $120M in Q3 2025, closing 2 positions and reducing 4 holdings. Its most notable exit was Third Harmonic Bio, an estimated $56.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Atlas Venture Life Science Advisors's biggest Q3 2025 reduction was Disc Medicine, cutting an estimated $14.4M.
- Atlas Venture Life Science Advisors fully exited Third Harmonic Bio in Q3 2025, selling an estimated $56.5M.
- Atlas Venture Life Science Advisors's ten largest holdings make up 100% of its $753M portfolio in Q3 2025.
- Atlas Venture Life Science Advisors opened 0 new positions and closed 2 in Q3 2025.
- Atlas Venture Life Science Advisors's portfolio value rose 14% quarter-over-quarter to $753M.
Based on Atlas Venture Life Science Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.